NYSE
92.83USD
+0.06 (+0.06%)
We have scored 85 news catalysts on Medtronic plc (MDT) over the past 12 months. The biggest single-day move next to one of them came Jul 28, 2026, when MDT closed +3.2%: “Intuitive Surgical Fell 37% to $355 With This Wall Street Pro Is Calling for $685”. Coverage across the window leans positive (average ticker sentiment +0.27). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
118.8B
P/E
—
EPS
—
Beta
0.57
52W range
73.31-106.33
Day range
92.03–93.04
Open
92.28
Prev close
92.77
Volume
2M
Avg volume
9.1M
Dividend
2.85
IPO
1973-05-02
Analysts publish price targets on MDT, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
23 analyst price targets from $80 to $115
as of 2026-09-09
The market is within 3% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Medtronic plc — not a sector bucket. Click an edge to see the articles that established the link.
Suppliers, customers, partners and competitors of Medtronic plc, taken from what the news actually said about them rather than from a sector bucket. The count is how many articles established each link.
Latest scored catalyst for MDT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
The price sits at the 43rd percentile of 23 published models, broadly endorsing the near-consensus that Medtronic delivers mid-single-digit organic growth, while explicitly refusing to pay for the 20–25% upside tied to robotics and diabetes upside.
What the disagreement turns on
Whether Medtronic can accelerate revenue growth beyond its guided 7.25%–7.75% via its robotics and diabetes platforms, which unit volume data can track, while the margin and separation upside remain unobservable with the wired tools.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
